US FDA warns co-administration of remdesivir and chloroquine phosphate or hydroxychloroquine sulfate may result in reduced antiviral activity of remdesivir

This potential drug interaction is based on a recently completed non-clinical laboratory study. The FDA is not aware of instances of this reduced activity occurring in the clinical setting but is continuing to evaluate all data related to remdesivir.

Source:

US Food and Drug Administration